Regency Centers is a preeminent national owner, operator, and developer of shopping centers located in suburban trade areas with compelling demographics. Our portfolio includes thriving properties merchandised with highly productive grocers, restaurants, service providers, and best-in-class retailers that connect to their neighborhoods, communities, and customers. Operating as a fully integrated real estate company, Regency Centers is a qualified real estate investment trust (REIT) that is self-administered, self-managed, and an S&P 500 Index member.

Regency Centers Corporation

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bristol-Myers Squibb (BMY – Research Report) and R...

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Regeneron (REGN)

Evercore ISI analyst Cory Kasimov maintained a Buy rating on Regeneron yesterday and set a price target of $875.00. The company’s shares closed yes...

Evercore ISI Keeps Their Buy Rating on Regeneron (REGN)

In a report released today, Louise Chen from Scotiabank maintained a Hold rating on Regeneron, with a price target of $770.00. According to TipRank...

Scotiabank Reaffirms Their Hold Rating on Regeneron (REGN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Regeneron (REGN – Research Report), Korro Bio (KRRO – Research Re...

Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Korro Bio (KRRO) and AstraZeneca (AZN)

Regeneron Pharmaceuticals (($REGN)) has held its Q4 earnings call. Read on for the main highlights of the call. Regeneron Earnings Call Strikes Con...

Regeneron’s Earnings Call: Growth Engines and Rising Costs

The latest update is out from Regis Healthcare Ltd. ( ($AU:REG) ). Regis Healthcare Limited has appointed experienced healthcare executive Carmel M...

Regis Healthcare Appoints Former Ramsay Executive Carmel Monaghan to Board

Citi analyst Geoff Meacham maintained a Buy rating on Regeneron today and set a price target of $900.00. Meacham covers the Healthcare sector, focu...

Citi Remains a Buy on Regeneron (REGN)

Macquarie analyst maintained a Buy rating on Regis Healthcare Ltd. today and set a price target of A$7.90. Currently, the analyst consensus on Regi...

Regis Healthcare Ltd. (REG) Gets a Buy from Macquarie

U.S. stocks finished the week mixed as gains in technology shares helped offset weakness in financial stocks and rising rate pressure. The Dow Jone...

The Week That Was, The Week Ahead: Macro and Markets, Jan. 25

Analysts fell to the sidelines weighing in on Becton Dickinson (BDX – Research Report) and Regeneron (REGN – Research Report) with neutral ratings,...

Analysts’ Top Healthcare Picks: Becton Dickinson (BDX), Regeneron (REGN)

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron’s latest clinical update centers on a Phase 1 tria...

Regeneron Explores New Intralesional Use for Libtayo in Skin Cancer: What Investors Should Know

In a report released yesterday, from BOCOM International Holdings Company maintained a Buy rating on RemeGen Co. Ltd. Class H, with a price target ...

BOCOM International Holdings Company Sticks to Their Buy Rating for RemeGen Co. Ltd. Class H (9995)

In a report released yesterday, from Zhongtai Securities upgraded RemeGen Co. Ltd. Class H to a Buy, with a price target of HK$114.00. The word on ...

RemeGen Co. Ltd. Class H (9995) was upgraded to a Buy Rating at Zhongtai Securities

RemeGen Co. Ltd. Class H ( ($HK:9995) ) just unveiled an announcement. RemeGen Co., Ltd. has completed a share repurchase plan for its A-shares on ...

RemeGen Completes RMB20 Million A-Share Buyback for Future Equity Incentives

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Regeneron (REGN – Research Report) and Ocugen (OCGN ...

Analysts’ Top Healthcare Picks: Regeneron (REGN), Ocugen (OCGN)

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Study Overview Regeneron Pharmaceuticals is running a Phase ...

Regeneron Advances Early-Stage Eye Drug Pozelimab in Geographic Atrophy Trial

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Regeneron, with a price target of $885.00. Tewari covers the Hea...

Jefferies Reaffirms Their Buy Rating on Regeneron (REGN)

In a report released yesterday, David Risinger from Leerink Partners reiterated a Buy rating on Regeneron. The company’s shares closed yesterday at...

Leerink Partners Remains a Buy on Regeneron (REGN)

Regis Healthcare Ltd. ( ($AU:REG) ) has provided an announcement. Regis Healthcare Limited has notified the market that 60,164 performance rights (...

Regis Healthcare Announces Lapse of 60,164 Performance Rights

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Avita Medical (RCEL – Research Report), OrthoPediatrics (KIDS – R...

Analysts Conflicted on These Healthcare Names: Avita Medical (RCEL), OrthoPediatrics (KIDS) and Regeneron (REGN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Nuvation Bio (NUVB – Research Report) and Regenero...

Analysts Offer Insights on Healthcare Companies: Nuvation Bio (NUVB) and Regeneron (REGN)

Scotiabank analyst Louise Chen maintained a Hold rating on Regeneron today and set a price target of $770.00. Chen covers the Healthcare sector, fo...

Scotiabank Remains a Hold on Regeneron (REGN)

Exchange-traded funds (ETFs) offer a huge—and often confusing—number of choices. TipRanks’ ETF AI Analyst narrows it down to three ETFs with Outper...

3 Best ETFs to Invest In, According to AI Analyst, 1/7/2026

Regis Healthcare Ltd. ( ($AU:REG) ) has issued an update. Regis Healthcare Limited has scheduled the release of its financial results for the half-...

Regis Healthcare Sets Date for FY26 Half-Year Results and Investor Briefing

Regeneron Pharmaceuticals ($REGN), Sanofi SA ($SNY) announced an update on their ongoing clinical study. Study Overview: Sanofi and Regeneron have ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	REG	$72.55	+0.79%	781.09K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	REG	$72.55	+0.8%	781.09K
3
4
5
6

REG

REG

No Data Available

Get Regency Centers Corporation Data in Excel

Get Regency Centers Corporation Data in Excel